Provider and Caregiver Connection™: Improving Outcomes in Idiopathic Pulmonary Fibrosis (IPF) Through a Patient-Centered, Team-Based Approach



Activity Overview

Idiopathic Pulmonary Fibrosis (IPF) is a rare and progressive fibrotic lung disease with a median survival of 2 ½ to 5 years, which is worse than most cancers. With nonspecific signs and symptoms including dyspnea and cough, diagnosis is challenging and often delayed.  While there is no cure, antifibrotic therapies can slow or halt disease progression and, along with supportive measures, improve patient’s quality of life. 
During this Patient Caregiver Connection® Medical Crossfire®, a multidisciplinary panel of expert faculty will share their insights on early, differential diagnosis and discuss clinical practice guideline updates which include conditional recommendations for the antifibrotic therapies pirfenidone and nintedanib. Faculty will then elaborate on the need for a multidisciplinary ‘ABCDE’ approach to address not only the range of co-morbidities associated with IPF but to provide comfort care that assesses and focuses on individual patient needs.  This activity is enhanced with a patient’s own story and perspective, from delays in diagnosis to daily challenges and advice for anyone burdened with a diagnosis of IPF.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Instructions for This Activity and Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, “educational content/video files” will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This CME activity is intended for IPF specialists, primary care physicians, physician assistants, nurse practitioners, nurses and other clinicians who treat patients with IPF.

Learning Objectives

Upon completion of this CME activity, you should be better prepared to:

  • List strategies for confirming an IPF diagnosis, including the utility of high-resolution computed tomography and surgical lung biopsy
  • Distinguish idiopathic from non-idiopathic forms by applying appropriate diagnostic testing, such as high-resolution CT scanning, to characterize distribution of fibrosis and inflammation
  • Apply current guidelines and new clinical evidence to develop a patient-centered, team approach plan for patients with IPF
  • Discuss new evidence and the status of emerging treatments for patients with IPF
  • Describe strategies to engage patients and facilitate a multidisciplinary approach to the management of IPF and associated comorbidities

Faculty, Staff, and Planners' Disclosures

Stephen Brunton, MD
Executive Vice President
Primary Care Education Consortium
Clinical Family Practice
Glendale and Downey, California
Disclosure: No relevant financial relationships with commercial interests.
Louis Kuritzky, MD
Clinical Assistant Professor Emeritus
University of Florida
Gainesville, Florida
Disclosure: No relevant financial relationships with commercial interests.
Steven Nathan, MD
Medical Director, Advanced Lung Disease and Lung Transplant Program
Professor of Medicine
Virginia Commonwealth University-Inova
Falls Church, Virginia
Disclosure: Grant/research support, consultant, member of speakers bureau: Boehringer Ingelheim, Inc. and Roche-Genentech.
Mary M. Salvatore, MD, MBA
Associate Professor of Radiology
Mount Sinai
New York, New York
Disclosure: member of speakers bureau: Genentech, Boehringer Ingelheim Inc. and Rockpointe.

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.


Become a Member

Forgot Password?
Calendar of Events
Filter By